Company: BGLC
Filing Date: 2025-04-30
Form Type: 8-K
Source: 0001477932-25-003114
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-30
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 30, 2025, BioNexus Gene Lab Corp. (the “ Company”) received a formal notice from the Nasdaq Hearings Panel (the “ Panel”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

The Company was previously notified of non-compliance with the Bid Price Rule and appeared before the Panel pursuant to Docket No. NQ 7050C-24. As of April 23, 2025, the Company’s common stock had maintained a closing bid price of $1.00 or greater for the requisite number of consecutive business days, thereby satisfying Nasdaq’s requirements for bid price compliance.

As a result, the Panel determined that the Company has demonstrated compliance with the terms of its exception and that its common stock will continue to be listed on The Nasdaq Capital Market. The Company remains subject to continued compliance with all applicable Nasdaq listing standards.

This disclosure is made pursuant to Item 3.01(b) of Form 8-K, as the Company has received formal written notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).

Item 7.01Regulation FD Disclosure.